AbbVie Provides Update Regarding RINVOQ (upadacitinib) for the Treatment of Moderate to Severe Atopic Dermatitis in the U.S.

Mount Carmel Register

Jul 16, 2021

AbbVie Provides Update Regarding RINVOQ (upadacitinib) for the Treatment of Moderate to Severe Atopic Dermatitis in the U.S. |!| Mount Carmel